Monoclonal antibody engineering company Xencor has signed a licensing and research partnership with Roche Group member Genentech to develop and commercialise the former’s lead cytokine product XmAB2403, an IL-15/IL-15 receptor alpha (Rα) with oncology indications, as well as other IL-15 cytokine therapies.

Under the terms of the agreement, Xencor and Genentech will co-develop XmAB2403 and other IL-15 products discovered during a two-year research programme; the companies will share the development costs and profits.

Genentech will be responsible for the commercialisation of the programmes globally, Xencor can choose to co-promote the therapies in the US.

Xencor will receive $120m upfront from Genentech, as well as being eligible to receive up to $160m in development milestones for XmAB2403 and $180m for other IL-15 products.

XmAB2403 was engineered using Xencor’s bispecific Fc domain and Xtend Fc tech. Combining IL-15 with IL-15Rα means the drug binds to IL-15Rß to stimulate the expansion and activation of natural killer cells and cytotoxic T cells.

Xencor claims its platforms produces IL-15 products, which are better tolerated by patients, how slower receptor mediated clearance and a longer half-life.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Roche global head of pharma partnering James Sabry said: “We believe cytokine therapy will play an important role in the treatment of a wide range of diseases, including cancer.

“This collaboration with Xencor will further enhance our understanding of a critical immune activation pathway and may present a potential new way to use the immune system to target cancer.”

Xencor president and chief executive Bassil Dahiyat said: “This partnership with Genentech accelerates our immuno-oncology work by enabling the exploration of novel XmAb24306 combinations with Genentech’s leading oncology portfolio and our growing internal pipeline of bispecific antibodies.

“A wide-ranging combination strategy will be critical to realize the potential of IL-15 bispecific cytokines such as XmAb24306, so we plan to explore our cytokines with a broad spectrum of leading commercial-stage and investigational cancer therapies.”

The deal remains subject to customary closing conditions, but is expected to be completed in the first half of 2019.

Xencor is currently co-developing other monoclonal antibody products for a range of indications with global pharma companies like Novartis, Amgen and Boehringer Ingelheim.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now